Bioventus LLC, a company specializing in orthobiologics, has announced the acquisition of BioStructures LLC, a maker of bioresorbable bone graft products for spinal and orthopedic applications. The agreement covers the entire portfolio of current products in addition to the company’s entire research and development pipeline. Employees of BioStructures will be given the opportunity to join Bioventus.
Bioventus Acquires BioStructures
1 min read Premium comments
Secondary
“The acquisition of BioStructures aligns with our strategy to be a leader in orthobiologics, building on the launch of the Bioventus Surgical business with the OsteoAMP acquisition in 2014, and our longer term development of the next generation BMP [bone morphogenetic proteins], ” said Tony Bihl, Bioventus CEO, in the November 30, 2015 news release. “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals.”
“This is a great event for BioStructures, Bioventus, our customers and our employees. We believe the combination of our product offerings will result in a truly unique and robust portfolio benefiting patients, surgeons and hospitals not found in the market today, ” said Russell Cook, BioStructures CEO. “This acquisition will continue to allow the culture of innovation, as well as advance the positive momentum we have built at BioStructures. We are happy to announce the transaction and look forward to the future with confidence and excitement.”
Regarding what impressed the company about BioStructures, Tony Bihl told OTW, “We were impressed with the broad portfolio of synthetic bone graft offerings and of the very robust R&D pipeline of new products, and then with the quality of the team and founders who created some of the best products we see in this market.”
“First priorities for us are to secure the ongoing product supply to physicians through the strong distribution channel in place, and welcome the BioStructures employees to Bioventus.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.